Last Price$437.20.0%
Market Cap$36.1B
LTM Free Cash Flow margin
20.5%
5Y avg
17.9%
Medical - Diagnostics & Research industry
median
(13.0%)
Stock quality & Intrinsic value
7/10
(0.5%) overvalued
IDEXX Laboratories, Inc. Free Cash Flow margin
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow margin | 11.6% | 14.5% | 5.2% | 7.5% | 5.2% | 11.2% | 12.6% | 9.9% | 12.5% | 12.2% | 11.8% | 8.3% | 15.2% | 15.1% | 12.5% | 12.6% | 20.0% | 19.8% | 11.7% | 21.1% |
Overvalued or undervalued?
Check the intrinsic value for IDXX
and see if it's the right time to invest.
IDEXX Laboratories, Inc. (IDXX) Free Cash Flow margin comparison analysis
General
LTM Free Cash Flow margin
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
IDEXX Laboratories, Inc.IDXX
20.5%
8.7%
25.2%
23.1%
Median Peer Set
16.4%
(1.7%)
(7.2%)
11.6%
Mettler-Toledo International Inc.MTD
22.3%
2.2%
12.7%
22.3%
Danaher CorporationDHR
22.2%
(0.1%)
(17.9%)
16.3%
Agilent Technologies, Inc.A
21.6%
(4.7%)
5.0%
19.8%
Waters CorporationWAT
20.9%
(0.5%)
(7.9%)
21.7%
Thermo Fisher Scientific Inc.TMO
16.9%
(4.6%)
(12.4%)
14.0%
Illumina, Inc.ILMN
15.9%
(2.9%)
4.6%
(28.0%)
IQVIA Holdings Inc.IQV
13.7%
2.8%
2.4%
8.9%
Quest Diagnostics IncorporatedDGX
9.2%
(6.4%)
(6.5%)
9.2%
Laboratory Corporation of America HoldingsLH
8.4%
(18.3%)
(65.8%)
3.4%
Natera, Inc.NTRA
(2.2%)
32.0%
(32.1%)
(40.2%)
IDXX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 549.2 0.0% | 638.1 16.2% | 739.1 15.8% | 922.6 24.8% | 1,024.0 11.0% | 1,031.6 0.7% | 1,103.4 7.0% | 1,218.7 10.4% | 1,293.3 6.1% | 1,377.1 6.5% | 1,485.8 7.9% | 1,601.9 7.8% | 1,775.4 10.8% | 1,969.1 10.9% | 2,213.2 12.4% | 2,406.9 8.8% | 2,706.7 12.5% | 3,215.4 18.8% | 3,367.3 4.7% | 3,661.0 8.7% |
| Cost of Goods Sold (COGS) | 270.2 | 315.2 | 359.6 | 459.0 | 494.3 | 505.4 | 524.8 | 572.2 | 594.2 | 620.9 | 669.7 | 711.6 | 800.0 | 871.7 | 971.7 | 1,041.4 | 1,135.6 | 1,325.9 | 1,363.0 | 1,471.0 |
% margin | 279.0 50.8% | 322.9 50.6% | 379.5 51.3% | 463.5 50.2% | 529.8 51.7% | 526.3 51.0% | 578.6 52.4% | 646.5 53.0% | 699.1 54.1% | 756.1 54.9% | 816.1 54.9% | 890.3 55.6% | 975.4 54.9% | 1,097.4 55.7% | 1,241.5 56.1% | 1,365.5 56.7% | 1,571.0 58.0% | 1,889.4 58.8% | 2,004.3 59.5% | 2,190.0 59.8% |
| Operating Expenses | 171.0 | 207.6 | 251.6 | 327.3 | 357.3 | 350.3 | 374.7 | 410.3 | 436.6 | 489.4 | 555.9 | 582.1 | 625.2 | 684.4 | 750.2 | 812.7 | 876.5 | 957.4 | 1,105.6 | 1,092.8 |
| Research & Development Expenses (R&D) | 35.4 | 40.9 | 53.6 | 67.3 | 70.6 | 65.1 | 68.6 | 76.0 | 82.0 | 88.0 | 98.3 | 99.7 | 101.1 | 109.2 | 117.9 | 133.2 | 141.2 | 161.0 | 254.8 | 191.0 |
| Selling, General & Administrative Expenses (SG&A) | 135.6 | 166.6 | 198.0 | 260.0 | 285.3 | 285.2 | 306.1 | 334.2 | 354.6 | 401.4 | 457.6 | 482.5 | 524.1 | 575.2 | 632.3 | 679.5 | 735.3 | 796.4 | 850.8 | 901.9 |
% margin | 108.0 19.7% | 115.3 18.1% | 127.9 17.3% | 136.2 14.8% | 172.5 16.8% | 176.0 17.1% | 203.9 18.5% | 236.2 19.4% | 262.6 20.3% | 266.8 19.4% | 260.3 17.5% | 299.9 18.7% | 350.2 19.7% | 413.0 21.0% | 491.3 22.2% | 552.8 23.0% | 694.5 25.7% | 932.0 29.0% | 898.8 26.7% | 1,097.1 30.0% |
| Interest Income | 3.1 | 3.1 | 0.0 | 0.0 | 2.3 | 0.5 | 0.7 | 1.7 | 1.9 | 1.9 | 1.7 | 2.5 | 3.7 | 5.3 | 1.2 | 0.4 | 0.6 | 0.4 | 1.1 | 5.6 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 4.6 | 1.4 | 1.8 | 1.8 | 1.9 | 3.5 | 13.7 | 26.8 | 28.4 | 32.0 | 33.6 | 30.6 | 32.5 | 29.4 | 38.8 | 41.6 |
| Pre-tax Income | 111.1 | 118.5 | 130.8 | 134.8 | 170.2 | 174.5 | 202.1 | 234.4 | 260.6 | 263.3 | 246.6 | 273.1 | 321.8 | 381.1 | 457.7 | 522.2 | 662.0 | 902.7 | 860.0 | 1,061.2 |
% effective tax rate | 33.2 29.9% | 40.7 34.3% | 37.2 28.5% | 40.8 30.3% | 54.0 31.7% | 52.3 30.0% | 60.8 30.1% | 72.7 31.0% | 82.3 31.6% | 75.5 28.7% | 64.6 26.2% | 81.0 29.7% | 99.8 31.0% | 117.8 30.9% | 80.7 17.6% | 94.4 18.1% | 79.9 12.1% | 157.8 17.5% | 180.9 21.0% | 216.1 20.4% |
% margin | 78.3 14.3% | 78.3 12.3% | 93.7 12.7% | 94.0 10.2% | 116.2 11.3% | 122.2 11.8% | 141.3 12.8% | 161.8 13.3% | 178.3 13.8% | 187.8 13.6% | 181.9 12.2% | 192.1 12.0% | 222.0 12.5% | 263.1 13.4% | 377.0 17.0% | 427.7 17.8% | 581.8 21.5% | 744.8 23.2% | 679.1 20.2% | 845.0 23.1% |
| EPS | 0.57 | 0.60 | 0.75 | 0.77 | 0.97 | 1.04 | 1.23 | 1.43 | 1.62 | 1.77 | 1.82 | 2.07 | 2.47 | 3.00 | 4.34 | 4.97 | 6.82 | 8.74 | 8.12 | 10.17 |
| Diluted EPS | 0.55 | 0.57 | 0.71 | 0.73 | 0.94 | 1.00 | 1.19 | 1.39 | 1.59 | 1.74 | 1.79 | 2.05 | 2.44 | 2.94 | 4.26 | 4.89 | 6.71 | 8.60 | 8.03 | 10.06 |
% margin | 126.5 23.0% | 139.7 21.9% | 157.7 21.3% | 177.3 19.2% | 223.6 21.8% | 226.2 21.9% | 250.5 22.7% | 284.7 23.4% | 316.2 24.4% | 322.3 23.4% | 319.8 21.5% | 370.3 23.1% | 431.7 24.3% | 501.4 25.5% | 575.7 26.0% | 643.7 26.7% | 793.8 29.3% | 1,039.9 32.3% | 1,014.5 30.1% | 1,217.7 33.3% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is IDEXX Laboratories, Inc.'s Free Cash Flow margin?
As of today, Microsoft Corp's last 12-month Free Cash Flow margin is 20.5%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Free Cash Flow margin for IDEXX Laboratories, Inc. have been 18.4% over the past three years, and 18.8% over the past five years.
2) Is IDEXX Laboratories, Inc.'s Free Cash Flow margin Good?
As of today, IDEXX Laboratories, Inc.'s Free Cash Flow margin is 20.5%, which is higher than industry median of (13.0%). It indicates that IDEXX Laboratories, Inc.'s Free Cash Flow margin is Good.